Sera Prognostics, Inc. (NASDAQ:SERA) Short Interest Down 18.2% in April

Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) was the recipient of a large decrease in short interest in April. As of April 15th, there was short interest totalling 786,000 shares, a decrease of 18.2% from the March 31st total of 960,700 shares. Currently, 3.4% of the company's shares are short sold. Based on an average trading volume of 111,000 shares, the short-interest ratio is currently 7.1 days.

Institutional Trading of Sera Prognostics

Institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp increased its position in shares of Sera Prognostics by 3.6% during the first quarter. Bank of New York Mellon Corp now owns 135,582 shares of the company's stock worth $499,000 after purchasing an additional 4,670 shares in the last quarter. Sanders Morris Harris LLC lifted its stake in Sera Prognostics by 4.0% in the first quarter. Sanders Morris Harris LLC now owns 94,200 shares of the company's stock valued at $347,000 after buying an additional 3,600 shares during the last quarter. Rhumbline Advisers grew its position in shares of Sera Prognostics by 10.7% during the first quarter. Rhumbline Advisers now owns 39,970 shares of the company's stock worth $147,000 after acquiring an additional 3,869 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Sera Prognostics in the 4th quarter valued at $1,285,000. Finally, AWM Investment Company Inc. raised its position in Sera Prognostics by 12.2% in the 4th quarter. AWM Investment Company Inc. now owns 585,134 shares of the company's stock valued at $4,763,000 after purchasing an additional 63,820 shares during the last quarter. Hedge funds and other institutional investors own 54.64% of the company's stock.

Sera Prognostics Stock Down 1.6 %

NASDAQ SERA traded down $0.04 during trading on Wednesday, hitting $2.48. The stock had a trading volume of 113,329 shares, compared to its average volume of 131,529. The company has a market capitalization of $93.41 million, a PE ratio of -2.51 and a beta of 0.99. The firm has a 50 day moving average price of $3.59 and a 200 day moving average price of $5.61. Sera Prognostics has a twelve month low of $2.46 and a twelve month high of $10.23.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last announced its earnings results on Wednesday, March 19th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.01 million. During the same quarter in the prior year, the firm posted ($0.25) earnings per share. On average, sell-side analysts anticipate that Sera Prognostics will post -0.96 earnings per share for the current year.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.